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Abstract
The H-RAS-like suppressor (HRASLS) subfamily consists of five enzymes (1–5) in humans and three (1, 3, and 5) in
mice and rats that share sequence homology with lecithin:retinol acyltransferase (LRAT). All HRASLS family members
possess in vitro phospholipid metabolizing abilities including phospholipase A1/2 (PLA1/2) activities and O-acyltransferase
activities for the remodeling of glycerophospholipid acyl chains, as well as N-acyltransferase activities for the production
of N-acylphosphatidylethanolamines. The in vivo biological activities of the HRASLS enzymes have not yet been fully
investigated. Research to date indicates involvement of this subfamily in a wide array of biological processes and, as a
consequence, these five enzymes have undergone extensive rediscovery and renaming within different fields
of research. This review briefly describes the discovery of each of the HRASLS enzymes and their role in
cancer, and discusses the biochemical function of each enzyme, as well as the biological role, if known.
Gaps in current understanding are highlighted and suggestions for future research directions are discussed.
Keywords: H-RAS-like suppressor enzymes, Acyltransferase, Phospholipase A1/2, Class II tumour suppressor,
N-acylphosphatidylethanolamine (NAPE), Pla2g16, TIG3, RARRES3, RIG1, iNAT
Introduction
The H-RAS-like suppressor (HRASLS) enzymes consist
of five members (1–5) in humans and three (1, 3, and 5)
in mice and rats [1, 2]. Also known as lecithin:retinol
acyltransferase (LRAT)-like proteins due to their se-
quence homology to LRAT (Fig. 1) [3], the HRASLS en-
zymes comprise a vertebrate subfamily of the papain-like
or NlpC/P60 thiol proteases that includes LRAT [4].
Enzymes in this superfamily have diverse functions,
forming a conserved group of homologous proteins
found broadly in the bacterial superkingdom, in DNA
and positive strand RNA viruses, in archaea, and in eu-
karyotes [4].
HRASLS family members share several common ele-
ments (Figs. 1, 2 and 3), including a highly conserved
NCEHFV sequence in the C-terminal region and similar
basic structural motifs [2, 3]. Several residues in the
NCEHFV sequence are critical for acylation and deacyla-
tion reactions, including the cysteine that acts as the
active site nucleophile [2]. This residue is paired in
HRASLS 2–5 with two N-terminal region histidines,
and in HRASLS1 with N-terminal region histidine
and asparagine residues, forming an unconventional
catalytic triad that is characteristic of NlpC/P60 fam-
ily members [4]. In this arrangement, the first histi-
dine acts as a base to deprotonate the sulfhydryl
group of the cysteine side chain, while the second
polar residue acts to stabilize the correct orientation
of the imidazole ring of the first histidine [2]. With
the exception of HRASLS5, these proteins also
contain a C-terminal transmembrane-spanning hydropho-
bic domain for endomembrane localization (Fig. 1) [5].
Currently, only the structures of HRASLS2, HRASLS3,
and HRASLS4 have been reported. The crystal structures
of HRASLS2 and HRASLS3 were solved by Golczak et al.
in 2012. They were both shown to contain three α-helices
well separated from a four-stranded antiparallel β-sheet,
which resembles the basic structure of the NlpC/P60 thiol
proteases that contain an α + β fold with segregated αβ
segments (Fig. 2) [3, 4]. The NMR structure of HRASLS4
was solved by Wei et al. in 2015 and showed similar
folding to that of HRASLS3, although the basic struc-
ture contained four α-helices and a six-stranded anti-
parallel β-sheet (Fig. 2) [6].
Recent evidence has indicated a biochemical role for
all HRASLS homologues in acyl chain remodeling of
glycerophospholipids [3]. Using mass spectrometry ana-
lysis, a thioester intermediate has been detected to form
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between cysteine 161 of purified LRAT and the acyl
side-chain donated by phosphatidylcholine (PC) [7].
This suggests that the transient acylation of a reactive
cysteine residue also occurs in the LRAT-like HRASLS en-
zymes to mediate reactions involving glycerophospholi-
pids (Fig. 4) [3]. HRASLS1-5 all possess in vitro Ca2+
independent phospholipaseA1/2 (PLA1/2) activities, which
requires a pH of 8–9, dithiothreitol (DTT), and Nonidet
P-40 for maximum function, and which are inhibited by
iodoacetate [8–10]. The importance of DTT in particular
suggests that preventing oxidation of sulfhydryl groups is
critical for maintaining enzyme stability, which agrees with
a predicted role for an active site cysteine in HRASLS en-
zymes [8]. Both PC and phosphatidylethanolamine (PE)
act as substrates with PLA1 activity showing dominance
over PLA2 activity for HRASLS1, 2, 4, and 5 [2, 8–11]. In
regards to HRASLS3, there has been contradictory evi-
dence of substrate specificity and positional preference for
acyl hydrolysis, as well as other enzymatic characteristics
[12–15]. Uyama et al. reported both PLA1/2 activities with
PC and PE as substrates, but a preference for hydrolysis at
the sn-1 position [15]. Duncan et al. also found that this
enzyme shows both PLA1/2 activities with maximal
phospholipase activity at pH 8, and they further identified
a broad range of possible substrates, showing evidence of
acyl hydrolase activity by HRASLS3/AdPLA against not
only PC and PE, but also phosphatidylserine, and phos-
phatidylinositol, but not phosphatidic acid [14]. However,
Fig. 1 Sequence alignment of human HRASLS enzymes. Sequence alignment was performed using ClustalW2 [51]. The C-terminal transmembrane-
spanning hydrophobic region is underlined. The NCEHFV motif is highlighted in red with the active site cysteine bolded and italicized. The remaining
two active sites in the catalytic triad are also bolded, and are highlighted in purple. Conserved residues are highlighted in yellow, and homologous
residues are highlighted in grey
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in contrast to the findings of Uyama et al., Duncan et al.
reported a preference for hydrolysis by this enzyme at the
sn-2 position that is moderately stimulated by Ca2+ [14].
The inconsistencies within the literature have been pro-
posed to be due to differences in the assay systems used
[15]. Based on the evidence to date, it seems that this en-
zyme should best be considered a PLA1/2 [14–16].
The HRASLS family of proteins also possess O-
acyltransferase activity, which describes the acyl-CoA in-
dependent transacylation of a lysophospholipid at either
the sn-1 or sn-2 position using a fatty acyl chain donated
by a phospholipid (Fig. 5) [1–3]. Each member of the
HRASLS family has shown some preference for O-
acylation of lysophosphatidylcholine (lyso PC) at the sn-
1 position [1, 8, 10]. It has therefore been proposed that
the HRASLS family be reclassified as a novel group of
phospholipid metabolizing enzymes, respectively known
as phospholipases A/acyltransferases (PLA/AT) 1–5 [1].
The HRASLS family of proteins also function in vitro
to differing extents as N-acyltransferases for the pro-
duction of N-acylphosphatidylethanolamines (NAPEs).
HRASLS1-5 have been shown to catalyze the transfer
Fig. 2 Structural alignment of human HRASLS enzymes. Sequence alignment was performed using ClustalW2 [51] and structural alignment was
performed for HRASLS2, HRASLS3, and HRASLS4 as described by Golczak et al. in 2012 [3] and Wei et al. in 2015 [6]. The β-sheets are indicated by
green arrows and α-helices are indicated by red lines
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of an acyl chain from the sn-1 position of a glyceropho-
spholipid to the amino group of PE producing NAPEs,
which serve as precursors for N-acylethanolamines
(NAEs) (Fig. 5) [1]. NAEs are a class of bioactive signal-
ling molecules produced when a NAPE molecule is
cleaved through hydrolysis, as catalyzed by NAPE-
hydrolyzing phospholipase D (NAPE-PLD) (Fig. 5). NAEs
have myriad biological roles, including modulation of in-
flammation, energy regulation, and nociception [1,
17]. Although little is yet known regarding the
physiological significance of NAE regulation by
HRASLS subfamily members, these enzymes are
already known to play diverse biological roles in vivo.
In particular, a function has been investigated for sev-
eral members as class II tumour suppressor genes.
Class II tumour suppressors are involved in the nega-
tive regulation of cell growth, and are often down-
regulated in cancer cells secondary to other genetic
or metabolic changes, but are not themselves mu-
tated or deleted. As a result, they make attractive
therapeutic targets, since they should be inducible if
appropriate conditions or agents are identified [18–
20]. Due to the study of HRASLS subfamily mem-
bers in wide ranging fields, rampant renaming has
occurred, with the result that there are now 27 dif-
ferent designations for these five enzymes (Table 1).
Here, we identify and review the biochemical and
biological role of these enzymes, and seek to disam-




HRASLS1 was originally discovered by Akiyama et al. in
1999 through differential display between two mouse
cell lines [21]. The 167-amino acid long protein was
named A-C1, and was found to be 46 % homologous
with a rat tumour suppressor protein called rat H-
rev107 (now also called HRASLS3, among other names
(see Table 1)) [11, 21]. The 168 aa-long human
HRASLS1/A-C1 gene was also cloned, and was found to
share 83 % identity with the mouse sequence [8, 22]. A
tumour suppressor role for HRASLS1/A-C1 was tested
directly and it was found that, indeed, overexpression of
HRASLS1/A-C1 inhibited the growth of H-Ras-trans-
formed NIH3T3 fibroblasts [21]. Additionally, expres-
sion of the human homolog was found to be reduced in
gastric cancers from 41 different individuals due to
hyper-methylation of CpG islands in the 5’ region of the
HRASLS1 gene, suggesting that it also plays a role as a
tumour suppressor in human disease [23].
The enzymological role was first assessed over a dec-
ade after HRASLS1 was cloned [8]. Reports demonstrate
a ratio of 1.6 [1] or higher [24] for human, mouse and
rat HRASLS1/AC-1 PE N-acyltransferase activity to PLA1/2
activity, indicating greater specific N-acyltransferase activity
in vitro [1, 24]. This is supported by metabolic labelling
experiments in cells [1, 2, 8, 24].
The tissue distribution of HRASLS1 is distinguishable
from other members of the HRASLS family of enzymes.
In humans, mice, and rats, HRASLS1/A-C1/PLA/AT1 is
Fig 3 Homology domains within the five human HRASLS enzymes. LRAT (lecithin:retinol acyltransferase) homology domain and the predicted
transmembrane region (TM region) are shown
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predominately expressed in testes, skeletal muscle, and
heart [8]. Humans show relatively low expression of
HRASLS1 in most other tissues [8], while mice and rats
also show abundant expression in brain, with some evi-
dence of expression in thymus, lung, stomach, kidney,
and bone marrow cells [8, 21]. N-acylethanolamines
(NAEs) are known to accumulate in response to acute
injury in tissues, including the heart, brain, and testicles,
suggesting a possible role for HRASLS-1 in mediating
pathological events in these tissues [17]. Thus far,
however, no studies have examined the physiological role
of HRASLS1.
HRASLS2 (PLA/AT2)
HRASLS2 was first cloned from SW480 colon cancer
cells [5]. This member of the HRASLS family is located
Fig 4 Illustration of a portion of the catalytic mechanism of HRASLS enzymes including depiction of the thioester intermediate formed during
phospholipid hydrolysis. Reaction demonstrating the formation of a thioester intermediate following nucleophilic attack by the anionic sulphur of
the deprotonated active site cysteine side chain in HRASLS proteins on the carbonyl group of the sn-1 fatty acyl chain of phosphatidylcholine.
Hydrolysis results in the generation of a free lysophospholipid and an enzyme-fatty acyl intermediate that releases the enzyme and a free fatty
acid following addition of a hydroxyl group to the carbonyl of the fatty acyl chain, forming a carboxylic acid. All HRASLS enzymes can catalyze
complete phospholipase reactions in vitro, resulting in liberation of a free fatty acid as well as a lysophospholipid. All HRASLS enyzmes also show
in vitro N- and O-acyltransferase activities, where the enzyme-fatty acyl intermediate binds a glycerolphospholipid leading to production of
N-acylphosphatidylethanolamines (NAPEs) or phospholipids, respectively
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on chromosome 11 in humans, but is lacking from the
rodent genome [5, 10]. The HRASLS2 gene transcript is
detectable primarily in gastrointestinal tissues, including
the colon, small intestine, and stomach, and is also
expressed in the trachea and kidney [5]. Subcellular
localization of HRASLS2 is primarily within the
perinuclear region, where it shows a granular pattern [5],
similar to that visualized for HRASLS1 [21].
A role for HRASLS2 in cancer and, specifically, in
RAS-mediated cellular transformation, has been inves-
tigated. Transfection of HRASLS2 into HCT166 colon






Fig 5 Examples of phospholipid metabolism reactions involving HRASLS enzymes. A, O-acyltransferase (acyl-CoA independent transacylase) reaction
demonstrating the conversion of lyso PC to PC, using the sn-1 acyl chain of PC as the acyl donor. B, N-acyltransferase reaction
demonstrating the acylation of the amino group of phosphatidylethanolamine using the sn-1 fatty acyl chain donated by PC,
resulting in the generation of an N-acylphosphatidylethanolamine (NAPE) and a lyso PC. C, Conversion of NAPE to N-acylethanolamine (NAE) by
NAPE-phospholipase D-mediated hydrolysis. D, Phospholipase A1 (PLA1) reaction demonstrating the cleavage of a fatty acyl chain from the sn-1
position of PC, resulting in the liberation of a free fatty acid and a 1-hydroxy-2-acyl-lyso PC. E, Phospholipase A2 (PLA2)-mediated conversion of PC to
lyso PC by hydrolysis of a fatty acyl chain at the sn-2 position
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breast cancer cells was shown to suppress colony
formation [5]. As well, HRASLS2 over-expression
suppressed the activation of wildtype and mutant
RAS in HtTA cervical cancer cells, resulting in in-
creased cell death [5]. These effects were dependent
on the C-terminal hydrophobic domain. Truncation
of the last 26 amino acids containing this region
eliminated the pro-apoptotic, anti-RAS, and growth
suppressive activities of HRASLS2 [5]. In addition,
loss of the putative C-terminal transmembrane do-
main also caused HRASLS2 to translocate, demon-
strating increased intensity in the nucleus, which
highlights the importance of this region in endomem-
brane localization [5].
The phospholipid metabolizing activities of HRASLS2
have been assessed using both cell homogenates and
purified enzyme. HRASLS2 overexpression in COS-7
cells was found to increase in vitro PLA1/2 activity, with
similar increases evident in assays conducted using
either post-microsomal supernatants or microsomal
pellets [10]. HRASLS2 was also shown to prefer to use
fatty acids from the sn-1 position of PC as acyl donors
for its N-acyltransferase activities [1, 10]. In vitro, N-
acyltransferase activity was found to be approximately
4-fold greater than PLA1/2 activity [1, 10]. Because of
the preference for activity at the sn-1 position, the major
N-acyl species of NAPE produced by the overexpression
of HRASLS2 in COS-7 cells tended to contain mostly
saturated and monounsaturated acyl chains, with N-
palmitoylethanolamide, N-stearoylethanolamide, and N-
oleoylethanolamide forming the predominant NAEs
generated, while N-arachidonoylethanolamide (i.e.
anandamide), and its precursor N-arachidonoyl PE,
showed only minimal elevation [1].
The physiological function of HRASLS2 is as-of-yet
uncharacterized. Overexpression of HRASLS2 in clonal
cell lines has been shown to decrease endogenous
plasmenylethanolamine levels, which causes abnormal
localization of peroxisomal proteins [1]. A similar result
has also been observed for HRASLS3 [12]. Since the
predominant activity of that enzyme is PLA1/2 rather
than N-acyltransferase activity, it is unlikely that changes
in NAPE/NAE levels or synthesis play a role in mediat-
ing peroxisomal events by HRASLS subfamily members.
Further studies with Hrasls2 gene ablation will be im-
portant to elucidate the biological role of this enzyme.
HRASLS3 (PLA/AT3)
Diverse studies on both the biological role and enzym-
atic function of HRASLS3 have led to the generation of
a particularly large number of aliases, with at least ten
different names recorded in the literature (Table 1)
[9, 13, 25]. HRASLS3 was the first of the HRASLS
subfamily of proteins to be discovered [11]. It was
identified by subtractive hybridization performed be-
tween H-ras transformed rat fibroblasts and pheno-
typic revertants that had regained density-dependent
growth inhibition, and thus was initially given the
name H-ras revertant #107 (H-rev 107) to denote this
[11]. In additional studies, HRASLS3/H-rev107 was
categorized as a class II tumour suppressor [11, 26]. It has
been suggested that HRASLS3 regulates oncogenic H-ras
Table 1 Aliases for the HRASLS family of enzymes
HRASLS-1 HRASLS-2 HRASLS-3 HRASLS-4 HRASLS-5
Aliases A-C1 PLA1/2-2 HRSL3 HRSL4 HRSL5
HRASLS PLA/AT-2 HREV107 TIG3 RLP-1
HRSL1 HREV107-1 RARRES3 HRLP5







Chromosomal location Human 3q29 Human 11q12.3 Human 11q12.3 Human 11q23 Human 11q13.2
Mouse 16 B2 Mouse 19 A Mouse 19 A
NM accession No.
(GenBank)
Human NM_020386.4 Human NM_017878.1 Human NM_001128203.1 Human NM_004585.4 Human NM_001146728.1
Mouse NM_013751.5 Mouse NM_139269.2 Mouse NM_025731.2
NP accession No.
(GenBank)
Human NP_065119.2 Human NP_060348.1 Human NP_001121675.1 Human NP_004576.2 Human NP_001140200.1
Mouse NP_038779.2 Mouse NP_644675.2 Mouse NP_080007.1
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through its ability to decrease cellular levels of ether-type
lipids, such as plasmalogens and monoalkyldiacyglycerols,
by decreasing cellular levels of peroxisomes that are major
sites for the synthesis of these lipids [12, 27]. Uyama et al.
found that HRASLS3 binds to the peroxisomal chaperone
protein Pex19p through its C-terminal and N-terminal
hydrophobic domains [27]. Subsequently, Pex19p is inhib-
ited from binding to peroxisomal membrane proteins such
as Pex3p and Pex11βp, which results in decreased peroxi-
somal biogenesis [27]. Additional studies, however, are still
required to directly test the relative importance of peroxi-
somal biogenesis regulation in mediating effects of
HRASLS3 on the H-ras-dependent growth of cancer cells.
HRASLS3 is downregulated in many cancers by
methylation of the CpG-rich region in the promoter,
which results in gene silencing [18, 28, 29]. In OVCAR-3
ovarian cancer cells, HRASLS3 has been show to interact
through its N-terminal proline-rich domain to ablate the
catalytic activity of protein phosphatase 2A [25], causing
caspase-9-dependent cell death. As well, HRASLS3 was
found to inhibit cell migration and invasion when
expressed in human NT2/D1 testicular cancer cells, and
this function was suggested to relate to its ability to
enhance the activity of prostaglandin D2 synthase
[30]. At least one study has demonstrated, using
chemical inhibitors, that the phospholipase activity of
HRASLS3/H-rev107 is required for its anti-RAS effect
[31]. This is also in agreement with an earlier finding
that the growth-inhibitory and tumor-suppressing ac-
tivity of HRASLS3/H-rev107 requires the C-terminal
region [26] that is required for catalysis [16].
Not all studies, however, have found an inhibitory role
for HRASLS3 in cancer. HRASLS3 does not inhibit, but
instead stimulates, the proliferation of non-small cell
lung carcinomas, contributing to tumour progression
[29]. HRASLS3 has also been found to be a downstream
target of mutant p53, with increased HRASLS3 levels
reported in p53 mutant osteosarcomas [32]. As well, in-
creased proliferation, migration, and invasion of osteo-
sarcoma cells was reported following overexpression of
HRASLS3 [32]. Additional studies on HRASLS3 active
site mutants in transformed cell lines will help to isolate
its lipid-enzymatic function from its function in tumour
growth modulation.
The enzymatic activity of HRASLS3/RLP-3 was first
investigated in 2007 by Jin et al., who demonstrated
N-acyltransferase activity for this enzyme in vitro [9].
Subsequent work indicated the predominance of PLA
over N- or O-acyltransferase activities for HRASLS3
in vitro [1, 8], and a detailed characterization of this
enzyme as an adipose-specific phospholipase A2 (AdPLA)
has been performed [14]. On the basis of studies
performed using general phospholipase chemical inhibi-
tors, it was suggested that this enzyme constituted the first
member of an entirely new group of phospholipases A2,
group XVI. As a result, the gene was subsequently
renamed PLA2G16 [14].
Highly detailed analyses of human HRASLS3 have
been performed in a series of elegant papers, including
X-ray crystallographic analysis of its structure [3, 16, 33].
In the first structure analysis of the HRASLS family
of proteins, Ren et al. demonstrated in 2010 that the
phospholipase active site of HRASLS3 contains a
Cys113-His23-His35 catalytic triad [33]. This finding
was supported by Pang et al. in 2012 who showed
that the phospholipase activity of HRASLS3 was me-
diated by this catalytic triad [16]. As is also seen in
LRAT-NlpC/P60 family proteins, the active-site cyst-
eine performs a nucleophilic attack on the sn-1 and
sn-2 acyl groups of phospholipids. In this reaction,
the pKa of Cys
113 is too high to allow it to act as a
nucleophile alone [16]. Thus, His23 assists in deproto-
nating the sulfhydryl side chain of Cys113, which ef-
fectively lowers the pKa from 8.3-8.8 to 7.0, allowing
it to function in the deacylation of phospholipids.
This study also provided mechanistic insight into the
higher phospholipase activity relative to acyltransfer-
ase activity of HRASLS3 in particular. Evaluation of
hydrogen/deuterium exchange at the active site of
HRASLS3 suggested that during catalysis, water could
readily access reactants, allowing the reactive intermediate
to decompose to a free fatty acid and a lysophospholipid
[16]. It remains to be determined whether varying degrees
of hydrophobicity at the active site are related to the acyl-
transferase/phospholipase activity ratio of other HRASLS
subfamily members. The C-terminal hydrophobic do-
main is critical for HRASLS3 activity. Truncation of
the C-terminal hydrophobic domain results in loss of
HRASLS3 from membranes, and a loss of HRASLS3-
mediated phospholipase activity in vitro, indicating
the critical nature of this hydrophobic span for inter-
facial catalysis [27].
The in vivo role of HRASLS3 has been studied in
some depth [13]. HRASLS3/AdPLA is expressed pre-
dominantly in white adipose tissue (WAT), and also to a
lesser extent in brown adipose tissue [13, 14], where it is
a major regulator of lipolysis and is crucial for the devel-
opment of obesity, as seen in an Hrasls3−/−/AdPLA−/−
mouse model [13]. The ablation of Hrasls3/AdPLA
causes a reduction in adipose tissue mass and triacyl-
glycerol content, despite normal adipogenesis, as a result
of constitutively elevated rates of lipolysis. The under-
lying molecular mechanism involves the regulation of
lipolysis through the modulation of prostaglandin E2
(PGE2) levels and signaling. HRASLS3/AdPLA is re-
sponsible for 80 % of adipocyte phospholipase activity,
which is a major source of arachidonic acid that is used
in the synthesis of eicosanoids [13]. As a result, loss of
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HRASLS3/AdPLA results in a dramatic fall in levels of
PGE2 [13]. The primary receptor for PGE2 in adipocytes
is prostaglandin E receptor 3 (EP3), which is unique
among EPs in that it is Gαi–coupled, and therefore ex-
erts a repressive action on adenylyl cyclase in adipocytes
when activated [34]. Thus, loss of HRASLS3/AdPLA in
mice causes a decrease in PGE2 levels and concomitant
reduced activation of inhibitory EP3, with the result that
generation of cAMP, activation of the hormone-sensitive
lipase, and stimulation of lipolysis proceeds unchecked,
preventing the accumulation of triacylglycerol and the
development of genetic or diet-induced obesity [13].
Since HRASLS3/AdPLA is normally stimulated by insu-
lin, increased activity by this enzyme may help to modu-
late the antilipolytic effects of insulin in adipocytes in
the fed state [13]. The role of HRASLS3/AdPLA in adi-
pocyte triglyceride metabolism suggests that inhibition
may be a useful strategy to prevent and treat obesity [13,
16], and future studies will therefore likely focus on the
design of inhibitors [16] and on strategies to regulate
this enzyme.
HRASLS4 (PLA/AT4)
HRALS4 was identified by three separate groups in 1998
[35], 2000 [36], and 2001 [37] as a retinoid-inducible
anti-proliferative/class II tumour suppressor gene that
goes by the alternate names Tazarotene-induced protein
3 (TIG3), Retinoic acid receptor responder protein 3
(RARRES3), and Retinoid-inducible gene 1 (RIG1) (see
Table 1 for all aliases). HRASLS4 is homologous with
HRASLS3/H-rev107 [35, 36] and, like that enzyme, has
reduced expression in a wide variety of primary human
tumours, including lymphoma, ureter, kidney, rectal, and
uterine, and cancer cell lines, including HL-60 promye-
locytic leukemia cells, HeLa cells, K-562 chronic myelog-
enous leukemia cells, SW480 colon carcinoma, A549
colon carcinoma, and G361 melanoma cells [35].
HRASLS4 also shows growth inhibitory effects when
overexpressed in T47D Chinese hamster ovary cells [35].
A role for HRASLS4 in malignant disease continues to
be studied extensively, and a comprehensive overview of
this area is beyond the scope of the current review.
However, it is of interest to mention some of the more
recent findings. The HRASLS4 promoter contains a re-
sponse element for the p53 tumour suppressor that is
activated by wildtype but not mutant p53 [38]. Whether
this feature exists for all HRASLS subfamily members
has not yet been studied, but it would help to explain
the almost universal down-regulation of these proteins
in transformed cells.
Like other HRASLS subfamily members, HRASLS4
also inhibits H-RAS-mediated signalling [5, 39, 40]. The
anti-cancer activity of HRASLS4 has been localized
specifically to its action within the Golgi. While the
C-terminal hydrophobic domain of HRASLS4 anchors
this enzyme within both the endoplasmic reticulum
and the Golgi apparatus, only Golgi-targeted HRASLS4
induces apoptosis in cancer cells [39]. The phospholipid
metabolizing activity of HRASLS4 appears to be im-
portant for its anti-cancer effects, particularly with
regards to metastasis and invasion [41]. Similar to
HRASLS3, HRASLS4 functionally interacts with prosta-
glandin D2 synthase to augment the production of
prostaglandin D2 [42]. This function was found to be
dependent on an intact C-terminal hydrophobic do-
main, and although not tested directly, it seems highly
likely to be related to the phospholipase activity of this
enzyme [42].
A role for HRASLS4 in phospholipid metabolism has
been investigated [1, 10]. HRASLS4 functions in vitro as
a Ca2+ independent PLA1/2 [1, 8, 10]. Although N-
acyltransferase activity in vitro has been shown to be
minor or absent for this enzyme [10], HRASLS4 does
significantly increase the cellular content of both NAPE
and NAE in metabolic labelling experiments [1]. The
functional significance of this activity with regards to the
anti-cancer activity of this enzyme remains to be
determined.
A physiological role for Hrasls4 has been investigated
[43]. HRASLS4 is found in the suprabasal epidermis of
skin, where it interacts with and activates another en-
zyme, transglutaminase I (TG1), which functions during
terminal differentiation to form covalent bonds between
proteins at the inner surface of the plasma membrane
[44]. The action of TG1 is critical for production of the
cornified envelope that maintains the epidermal barrier
[44], and adenoviral delivery of HRASLS4 to cultured
keratinocytes results in the activation of TG1, resulting
in differentiation-like cell death, as well as the generation
of cornified envelope-like structures [45, 46]. Reduced
expression of HRASLS4 is evident in hyperproliferative
conditions such as psoriasis [47]. An additional role for
HRASLS4 in keratinocyte differentiation is suggested
by findings that this protein also localizes to the centro-
some, where it affects microtubule kinetics and cell div-
ision [43, 48]. Interaction between the centromere and
HRASLS4 has been found to involve a central region of
the enzyme that contains the NCEHFV sequence [43].
However, whether the phospholipid metabolizing abil-
ities of this enzyme, per se, are critical for its various
physiological roles in skin cells, remains to be clearly
characterized.
HRASLS5 (PLA/AT5)
HRASLS5 was first investigated as part of a search for
new Ca2+-independent enzymes active in the N-acylation
of PE [9] (also called RLP-1 and iNAT; see Table 1 for all
aliases). HRASLS5 displays dominate N-acyltransferase
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activity over both PLA1/2 and O-acylation activities in
vitro, and overexpression of HRASLS5 enhances forma-
tion of NAPE and NAE in cultured cells [1, 2, 8, 9]. How-
ever, HRASLS5 differs from other HRASLS family
members in that it is predominantly present in the cytosol,
likely due to the absence of the C-terminal hydrophobic
span that is characteristic of HRASLS enzymes 1–4
(Figs. 1, 2, 3 and 4) [1, 9]. HRASLS5 also does not show a
clear preference for abstraction of acyl groups from ei-
ther the sn-1 or sn-2 positions of PC during N-
acylation reactions [9]. It has been suggested that
HRASLS5 may be involved in the production of anan-
damide (arachidonoyl ethanolamide) because of its cap-
acity to utilize fatty acyl chains from the sn-1 or sn-2
position of phospholipids [9]. However, studies have yet
to characterize the nature of endogenous NAPE and
NAE species produced by HRASLS5. Likewise, little is
known regarding the physiological function of this en-
zyme. It has been identified in spermatocytes of devel-
oping rat testes, but its function in that tissue is
currently unknown [49]. Similarly, studies have yet to
investigate whether it has a role in cancer like the other
HRASLS family members.
Conclusions
The five members of the HRASLS family of enzymes
have been shown to have phospholipase A1/2 activity,
and O- and N-acyltransferase activity. In addition, stud-
ies generally report reduced expression of these enzymes
in cancer cells, and demonstrate a direct anti-cancer
role, although not all studies agree. Evidence from
studies using mutated or truncated forms of HRASLS
subfamily members suggests that the phospholipid me-
tabolizing functions are required for some, but likely not
all, of the effects observed in tumour cells. Further work
should integrate recent advances in understanding the
biochemical function of these enzymes to better under-
stand mechanisms related to aberrant cell growth in neo-
plasia. Further studies should also focus on understanding
the major physiological function of each homologue in
cells and tissues, using recent advances in gene editing
techniques as well as the generation of gene knockout
mice. Human monozygotic twins with Poland Syndrome
have been found to be heterozygous for a gene deletion
event on chromosome 11 that removes HRASLS2-5,
strongly suggesting a role for one or more of these genes
in causation of this disorder [50]. Poland Syndrome is
characterized by hypoplasia/aplasia of the pectoralis major
muscle and other variable anomalies including hypopla-
sia/aplasia of mammary tissue and ribs, limited subcutane-
ous fat, and sternal anomalies [50]. Generation of gene
knockout mice will be required to understand any putative
role for this enzyme subfamily in normal physiology and
in human disease.
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